MedTrace Logo

To Study Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1656 in Japanese Type 2 Diabetes Mellitus (T2DM) Patients

NCT00916604 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2009-11-03

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and tolerability of AZD1656 after multiple repeated oral doses in Japanese patients with type 2 diabetes.

Conditions

Interventions

DRUG

AZD1656

Three increasing dose-steps with oral suspension, 8 days treatment

DRUG

Placebo

Placebo oral suspension, 8 days treatment

Sponsors & Collaborators

Principal Investigators

  • Klas Malmberg, MD · AstraZeneca R&D Mölndal

  • Takashi Eto, MD, PhD · PS Clinic, Fukuoka, Japan

  • Mitsuyasu Hokamura, MD · HONJO CLINIC II, Tokyo, Japan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-05-31
Completion
2009-10-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00916604 on ClinicalTrials.gov